Couverture de This $2 Billion Cancer Discovery Makes Radiation Look Outdated

This $2 Billion Cancer Discovery Makes Radiation Look Outdated

This $2 Billion Cancer Discovery Makes Radiation Look Outdated

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

Something most cancer patients are never told:
the radiation plan you receive is often influenced by the machine a hospital owns, not by what’s best for your cancer biology.


Dr. Dino Prato breaks down the radiation wars — and introduces a disruptive technology that may change oncology entirely: ultrasound-based tumor destruction. Data shows that 40–50% of radiation therapy is palliative, meaning it’s designed to slow disease or reduce symptoms rather than eliminate cancer. The real question becomes: what are we doing during that time?

Dr. Prato explains why radiation has long been an adjuvant tool, how hospital economics and reimbursement drive its overuse, and why newer technologies often struggle to gain adoption. He then introduces histotripsy and sonodynamic therapy, which use focused sound waves to “melt” tumors without radiation. This process creates a tumor lysate rich in antigens, neoantigens, and DAMPS — powerful immune signals that can be repurposed into systemic immunotherapy.

Using precision oncology principles — DNA sequencing, RNA transcriptomics, immune profiling, spatial biology, and AI-guided analysis — this lysate can be combined with immunotherapy, phytotherapeutic adjuvants, and nanoparticle delivery to stimulate whole-body immune response, not just local tumor control.

This episode explores why ultrasound-based approaches may replace large portions of radiation oncology in the future, why adoption is slow, and how immune-centric precision care shifts cancer treatment from palliative delay to strategic immune activation.

🎯 What You’ll Learn in This Episode:
• Why 40–50% of radiation therapy is palliative
• How hospital ownership influences radiation decisions
• The difference between radiation destruction and immune training
• What histotripsy and sonodynamic therapy are
• How tumor lysate becomes immunotherapy
• Why ultrasound avoids many radiation side effects
• How precision oncology integrates sound, data, and immunity
• Why disruptive cancer technology takes years to reach patients

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more:
www.envita.com
📞 Speak with a care coordinator: 866-830-4576


Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493

Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Aucun commentaire pour le moment